Effects of Tislelizumab injection combined with Lenvatinib mesylate capsules in treatment of elderly patients with advanced primary liver cancer
Objective:To observe effects of Tislelizumab injection combined with Lenvatinib mesylate capsules in treatment of elderly patients with advanced primary liver cancer.Methods:A prospective study was conducted on 96 elderly patients with advanced primary liver cancer admitted to this hospital from May 2021 to February 2023.According to the random number table method,they were divided into study group and control group,48 cases in each group.The control group was treated with Lenvatinib mesylate capsules,while the study group was treated with Tislelizumab injection on the basis of the control group.The objective remission rate,the serum tumor markers[carbohydrate antigen 19-9(CA19-9),alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA)]levels,the T cell subset levels,and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the levels of serum CA19-9,AFP and CEA in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the level of CD8+ in the two groups was lower than that before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the objective remission rate and the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tislelizumab injection combined with Lenvatinib mesylate capsule in the treatment of the elderly patients with advanced primary liver cancer can reduce the levels of serum tumor markers and improve the levels of T cell subsets.Moreover,it is superior to single Lenvatinib mesylate capsules treatment.
万方数据
维普
